Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection [Phase 2]

View source ↗

Summary

Phase 2 trial assessing ABT-493 and ABT-530 with/without ribavirin in HCV genotypes 1, 4, 5, and 6; completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ABT-493
• ABT-530
• Ribavirin (ribavirin)

Snippet

Sponsor: AbbVie | Conditions: Chronic Hepatitis C, Hepatitis C Virus | Phase 2 | Status: COMPLETED | Results posted: 2017-04-06